In the IMT case (12), the patient, who had confirmed a diagnosis of a DCTN1–ALK fusion through genetic profiling, was enrolled in a phase I clinical trial (ClinicalTrials.gov Identifier: NCT01548144) of crizotinib in combination with pazopanib. Here, ALK is linked to inflammatory myofibroblastic tumor.